Aperio Group LLC Boosts Stake in Catalent, Inc. (NYSE:CTLT)

Aperio Group LLC grew its stake in Catalent, Inc. (NYSE:CTLT) by 15.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,098 shares of the company’s stock after buying an additional 8,624 shares during the period. Aperio Group LLC’s holdings in Catalent were worth $5,577,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Catalent by 2.5% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 4,919 shares of the company’s stock worth $361,000 after purchasing an additional 122 shares during the last quarter. Park Avenue Securities LLC raised its holdings in shares of Catalent by 4.0% during the third quarter. Park Avenue Securities LLC now owns 4,322 shares of the company’s stock worth $370,000 after purchasing an additional 168 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Catalent by 133.3% during the second quarter. Signaturefd LLC now owns 385 shares of the company’s stock worth $28,000 after purchasing an additional 220 shares during the last quarter. Nissay Asset Management Corp Japan ADV raised its holdings in shares of Catalent by 1.5% during the third quarter. Nissay Asset Management Corp Japan ADV now owns 16,331 shares of the company’s stock worth $1,399,000 after purchasing an additional 245 shares during the last quarter. Finally, Shilanski & Associates Inc. raised its holdings in shares of Catalent by 2.1% during the second quarter. Shilanski & Associates Inc. now owns 13,098 shares of the company’s stock worth $960,000 after purchasing an additional 273 shares during the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE CTLT opened at $103.33 on Friday. The company’s 50-day simple moving average is $95.10 and its 200-day simple moving average is $83.82. Catalent, Inc. has a 52-week low of $31.04 and a 52-week high of $120.48. The firm has a market cap of $17.02 billion, a price-to-earnings ratio of 65.82, a price-to-earnings-growth ratio of 2.52 and a beta of 1.59. The company has a quick ratio of 2.14, a current ratio of 2.56 and a debt-to-equity ratio of 0.97.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 3rd. The company reported $0.43 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.06. Catalent had a net margin of 9.25% and a return on equity of 14.20%. The business had revenue of $845.70 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter last year, the business earned $0.26 earnings per share. The company’s revenue for the quarter was up 27.2% compared to the same quarter last year. Equities research analysts anticipate that Catalent, Inc. will post 2.28 EPS for the current fiscal year.

CTLT has been the subject of several recent research reports. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $114.00 target price for the company in a report on Tuesday, November 10th. Jefferies Financial Group raised their target price on shares of Catalent from $107.00 to $115.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Robert W. Baird raised their price target on shares of Catalent from $100.00 to $109.00 and gave the company an “outperform” rating in a research report on Wednesday, November 4th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Catalent from $91.00 to $100.00 and gave the company a “hold” rating in a research report on Thursday, November 5th. Finally, Argus raised their price target on shares of Catalent from $100.00 to $110.00 in a research report on Thursday, September 24th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $106.44.

In other news, CEO John R. Chiminski sold 182,231 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $86.01, for a total value of $15,673,688.31. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Michael J. Grippo sold 2,250 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $89.50, for a total transaction of $201,375.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 211,858 shares of company stock worth $18,387,619. Company insiders own 1.00% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Featured Story: Understanding Analyst Ratings

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.